AIM Selling General Administrative vs Total Revenue Analysis
0A4Y Stock | 0.22 0.01 4.35% |
AIM ImmunoTech financial indicator trend analysis is way more than just evaluating AIM ImmunoTech prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AIM ImmunoTech is a good investment. Please check the relationship between AIM ImmunoTech Selling General Administrative and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy AIM Stock please use our How to Invest in AIM ImmunoTech guide.
Selling General Administrative vs Total Revenue
Selling General Administrative vs Total Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AIM ImmunoTech Selling General Administrative account and Total Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between AIM ImmunoTech's Selling General Administrative and Total Revenue is -0.46. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Total Revenue in the same time period over historical financial statements of AIM ImmunoTech, assuming nothing else is changed. The correlation between historical values of AIM ImmunoTech's Selling General Administrative and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of AIM ImmunoTech are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Selling General Administrative i.e., AIM ImmunoTech's Selling General Administrative and Total Revenue go up and down completely randomly.
Correlation Coefficient | -0.46 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Selling General Administrative
Total Revenue
Total revenue comprises all receipts AIM ImmunoTech generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most indicators from AIM ImmunoTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AIM ImmunoTech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy AIM Stock please use our How to Invest in AIM ImmunoTech guide.Selling General Administrative is likely to drop to about 8 M in 2024
AIM ImmunoTech fundamental ratios Correlations
Click cells to compare fundamentals
AIM ImmunoTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AIM ImmunoTech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.2M | 13.8M | 20.8M | 64.6M | 74.3M | 78.0M | |
Total Current Liabilities | 5.3M | 1.1M | 1.1M | 673K | 605.7K | 575.4K | |
Total Stockholder Equity | 8.7M | 5.2M | 13.4M | 61.3M | 70.5M | 74.0M | |
Retained Earnings | (318.6M) | (327.6M) | (342.0M) | (361.1M) | (325.0M) | (341.2M) | |
Cash | 1.4M | 299K | 1.5M | 38.5M | 44.3M | 46.5M | |
Other Assets | 1.4M | 1.9M | 748K | 1.3M | 1.2M | 1.1M | |
Cash And Short Term Investments | 2.1M | 1.8M | 8.8M | 39.0M | 44.9M | 47.1M | |
Short Term Investments | 695K | 1.5M | 7.3M | 501K | 576.2K | 547.3K | |
Capital Surpluse | 317.4M | 323.7M | 340.2M | 402.5M | 462.9M | 374.0M | |
Total Liab | 5.5M | 8.7M | 7.3M | 3.3M | 3.8M | 6.2M | |
Total Current Assets | 3.8M | 10.4M | 40.3M | 50.2M | 57.7M | 60.6M | |
Intangible Assets | 858K | 912K | 1.2M | 1.5M | 1.7M | 1.2M | |
Common Stock | 1K | 10K | 42K | 48K | 55.2K | 29.0K | |
Property Plant Equipment | 7.8M | 7.3M | 6.7M | 4.2M | 3.8M | 5.9M | |
Other Liab | 1.1M | 57K | 180K | 35K | 31.5K | 29.9K | |
Net Tangible Assets | 4.3M | 11.5M | 59.1M | 54.2M | 62.3M | 65.4M | |
Accounts Payable | 680K | 472K | 383K | 198K | 178.2K | 169.3K | |
Net Receivables | 1.1M | 820K | 1.1M | 1.6M | 1.9M | 1.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AIM Stock Analysis
When running AIM ImmunoTech's price analysis, check to measure AIM ImmunoTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AIM ImmunoTech is operating at the current time. Most of AIM ImmunoTech's value examination focuses on studying past and present price action to predict the probability of AIM ImmunoTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AIM ImmunoTech's price. Additionally, you may evaluate how the addition of AIM ImmunoTech to your portfolios can decrease your overall portfolio volatility.